Provided are methods of treating frontotemporal lobar degeneration (FTLD) or frontotemporal dementia (FTD) using dibenzooxazepine compounds of the general formula (IV), where the variables are as defined in the specification. Examples of the compounds include (Z)-4-(dibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide and (Z)-N-hydroxy-4-(5-(2-morpholinoethyl)-5H-dibenzo[b,e][1,4]diazepin-11-yl)benzamide. Further, provided is the use of compounds such as 2-((1S,4S)-5-benzyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)-N-hydroxypyrimidine-5-carboxamide, N-hydroxy-N-methyl-4-((1S,4S)-5-p-tolyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)benzamide, (Z)-4-(8-chloro-5H-dibenzo[b,e][1,4]diazepin-11-yl)-N-hydroxybenzamide and (Z)-4-(benzo[f]thieno[2,3-b][1,4]oxazepin-5-yl)-N-hydroxybenzamide in the treatment of FTLD or FTD.
Methods of targeted treatment of frontotemporal lobar degeneration